CERE - Cerevel Therapeutics reports Q1 results
Cerevel Therapeutics (CERE): Q1 GAAP EPS of -$0.40.Cash and cash equivalents as of March 31, 2021 were $343.4M.Press Release
For further details see:
Cerevel Therapeutics reports Q1 resultsLink your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Stock Information
Get CERE Alerts
News, Short Squeeze, Breakout and More Instantly...